Physician profile
Rohit Sud
NPI 1477625465
$34,263.10
in general payments reported to CMS, 2019-2025
68 companies · $15K in 2025
The $15K reported for 2025 was more than what 91% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $938 · 2020: $653 · 2021: $1,903 · 2022: $2,572 · 2023: $2,517 · 2024: $10K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Food and Beverage: $5,845 · Honoraria: $2,335 · Travel and Lodging: $971 · Education: $128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,918.00 |
| Food and Beverage | $5,845.29 |
| Honoraria | $2,335.00 |
| Travel and Lodging | $970.89 |
| Education | $127.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $13,201.42 | 2019-2025 | Imfinzi, Lynparza, Calquence |
| Exelixis INC. | $3,330.82 | 2019-2025 | Cabometyx |
| Beigene USA, INC. | $3,142.75 | 2022-2024 | Brukinsa |
| Genmab U.S., INC. | $1,575.00 | 2025 | Epkinly |
| Bayer Healthcare Pharmaceuticals INC. | $1,428.08 | 2020-2025 | |
| Daiichi Sankyo INC. | $1,383.08 | 2020-2025 | Vanflyta, Enhertu, Datroway |
| Celgene Corporation | $841.23 | 2019-2025 | Reblozyl, Opdualag |
| Janssen Biotech, INC. | $654.12 | 2019-2025 | Darzalex, Rybrevant, Erleada |
| Novartis Pharmaceuticals Corporation | $575.62 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $570.65 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Beigene, Ltd. | $525.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $510.78 | 2019-2025 | Opdivo |
| Blueprint Medicines Corporation | $471.71 | 2021-2025 | Ayvakit |
| Abbvie INC. | $412.84 | 2019-2025 | Venclexta |
| Genzyme Corporation | $349.58 | 2020-2025 |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $265.64 | 2019-2025 | Itovebi, Polivy, Lunsumio |
| Sobi, INC | $252.35 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $237.13 | 2020-2025 | Libtayo |
| Eisai INC. | $234.97 | 2019-2024 | |
| Amgen INC. | $232.54 | 2019-2023 | Kyprolis, Blincyto |
| Glaxosmithkline, LLC. | $223.92 | 2021-2025 | Ojjaara, Zejula, Blenrep |
| Pfizer INC. | $223.12 | 2021-2024 | |
| Caris Mpi, INC. | $219.82 | 2025 | Mi Cancer Seek |
| Incyte Corporation | $214.30 | 2019-2025 | Monjuvi, Pemazyre, Jakafi |
| Takeda Pharmaceuticals U.S.A., INC. | $200.74 | 2019-2025 | Ninlaro, Iclusig, Alunbrig |
| Rigel Pharmaceuticals, INC. | $193.99 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Pharmacyclics LLC, An Abbvie Company | $192.71 | 2019-2023 | Imbruvica, Epkinly |
| Gilead Sciences, INC. | $184.68 | 2019-2025 | Trodelvy |
| Kite Pharma, INC. | $156.35 | 2020-2023 | |
| Tersera Therapeutics LLC | $152.00 | 2021-2025 | Zoladex |
| Seagen INC. | $146.68 | 2021-2023 | Padcev, Tukysa, Adcetris |
| Array Biopharma INC | $144.70 | 2022-2025 | Mektovi, Braftovi, Tukysa |
| Astellas Pharma US INC | $135.11 | 2020-2024 | Xospata |
| Ipsen Biopharmaceuticals, INC | $127.24 | 2020-2025 | Onivyde |
| Mirati Therapeutics, INC. | $120.28 | 2023-2024 | Krazati |
| Lilly USA, LLC | $107.11 | 2021-2025 | Verzenio, Retevmo, Jaypirca |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.14 | 2019-2024 | Gilotrif |
| Aveo Pharmaceuticals, INC. | $92.13 | 2022-2025 | |
| Karyopharm Therapeutics INC. | $91.38 | 2021-2024 | Xpovio |
| Emd Serono, INC. | $86.40 | 2020-2025 | |
| Sun Pharmaceutical Industries INC. | $77.83 | 2020-2023 | Odomzo, Yonsa |
| Stemline Therapeutics INC. | $76.97 | 2023-2025 | Orserdu |
| Puma Biotechnology, INC. | $72.47 | 2019-2025 | |
| Intuitive Surgical, INC. | $68.89 | 2022 | |
| G1 Therapeutics, INC. | $57.59 | 2022 | |
| Springworks Therapeutics, INC. | $52.57 | 2024-2025 | Ogsiveo |
| Legend Biotech USA INC. | $44.43 | 2025 | Carvykti |
| Taiho Oncology, INC. | $41.41 | 2022-2023 | |
| Jazz Pharmaceuticals INC. | $40.82 | 2020-2022 | |
| Cti Biopharma Corp. | $38.73 | 2023 | Vonjo |
| Pharmaessentia USA Corporation | $36.51 | 2024-2025 | Besremi |
| Geron Corporation | $33.44 | 2025 | Rytelo |
| Immunocore Limited | $33.24 | 2025 | Kimmtrak |
| Alexion Pharmaceuticals, INC. | $27.69 | 2020-2023 | Ultomiris |
| Roche Diagnostics Corporation | $24.99 | 2020 | |
| Epizyme, INC. | $24.15 | 2021 | |
| Dendreon Pharmaceuticals LLC | $22.53 | 2025 | Provenge |
| Dova Pharmaceuticals | $21.24 | 2021 | |
| Adaptive Biotechnologies Corporation | $20.12 | 2025 | Clonoseq |
| Cumberland Pharmaceuticals, INC. | $19.85 | 2025 | Sancuso |
| Myovant Sciences INC. | $19.77 | 2021 | |
| Adc Therapeutics America, INC. | $17.40 | 2023 | |
| Beone Medicines USA, INC. | $17.33 | 2025 | Brukinsa |
| Janssen Pharmaceuticals, INC | $14.13 | 2024 | Xarelto |
| Verastem, INC. | $13.13 | 2019 | |
| Tactile Systems Technology INC | $12.31 | 2021 | |
| Amag Pharmaceuticals, INC. | $11.42 | 2021 | |
| Organon LLC | $10.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohit Sud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.